Share this Job

Veterinary Pathologist II

Req ID:  38917
Location: 

Tranent, ELN, GB, EH33 2NE

For nearly 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Salary for this position will be dependent upon qualifications and/or relevant experience.

 

In this role, you will evaluate the gross and histopathological findings of toxicology and target animal safety studies.  This involves some non-routine techniques such as, immunohistochemistry, immunofluorescence and electron microscopy, liaison with other departments within the Company, and contact with external research institutes. You will have the opportunity to contribute to the training of technical staff and trainee Study Directors. Specialisation in a particular area of pathology will be encouraged. You will be required to support studies parented by our Edinburgh site however there may be necessity to travel for short periods (2-3 days) to our other European Charles River sites, to supervise specialised necropsy sessions or perform Peer reviews. You will prepare, review, and improve Standard Operating Procedures and protocols, and advance the scientific work of the site through method validation/innovation. You will be expected to contribute to the team’s reputation through peer-reviewed publications, conference presentations, and specialization in a particular area of toxicologic pathology.

 

You must have a Veterinary degree (BVSc, BVM&S, BVMS, DVM or equivalent), and Pathology Boards (FRCPath, ECVP, JCVP, JSTP or ACVP). You will be registrable with the UK Royal College of Veterinary Surgeons (MRCVS) and preferably have experience in toxicologic pathology or postgraduate experience in pathology (MSc or PhD). 

 

CLOSING DATE: 9/19/2018

About Safety Assessment

Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market.  Each year approximately 120 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.

About Charles River

Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.

With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges.  Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015. 

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.

For more information, please visit www.criver.com.